CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2020– Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of…Original Article
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
